Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rosuvastatin/choline fenofibrate - Abbott Laboratories/AbbVie/AstraZeneca

Next Previous
Drug Profile

Rosuvastatin/choline fenofibrate - Abbott Laboratories/AbbVie/AstraZeneca

Alternative Names: ABT-143; ABT-335/rosuvastatin; Certriad; choline-fenofibrate/rosuvastatin; Rosuvastatin/ABT-335; Rosuvastatin/fenofibric acid delayed release

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories; AstraZeneca
  • Class Antihyperlipidaemics; Chlorobenzenes; Ethanolamines; Fibric acid derivatives; Fluorobenzenes; Propionates; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action HMG-CoA reductase inhibitors; Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hyperlipidaemia

Most Recent Events

  • 22 Dec 2010 Discontinued - Preregistration for Hyperlipidaemia in USA (PO)
  • 30 Mar 2010 AstraZeneca & Abbott receive complete response letter from the FDA for rosuvastatin/choline fenofibrate in Hyperlipidaemia
  • 19 Jun 2009 Post-hoc efficacy data from two phase III trials in Dyslipidaemia presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA-2009)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top